Craft

Calithera Biosciences

Stock Price

$0

2024-02-28

Market Capitalization

$97.5 K

2024-02-28

Revenue

$9.8 M

FY, 2021

Calithera Biosciences Summary

Company Summary

Overview
Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. Calithera is currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, the Company's lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Calithera Biosciences's ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.
Type
Public
Status
Active
Founded
2010
HQ
South San Francisco, CA, US | view all locations
Website
http://www.calithera.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Susan M. Molineaux

    Susan M. Molineaux, Founder, President and Chief Executive Officer, Director

  • Keith Orford
  • Emil T. Kuriakose

    Emil T. Kuriakose, Chief Medical Officer

  • Christopher J. Molineaux

    Christopher J. Molineaux, Senior Vice President of Development

Operating MetricsView all

Phase I/II Trials Products

1

FY, 2016

Phase I Trials Products

1

FY, 2016

LocationsView all

1 location detected

  • South San Francisco, CA HQ

    United States

    343 Oyster Point Blvd #200

Calithera Biosciences Financials

Summary Financials

Net income (FY, 2022)
($39.7M)
Cash (FY, 2022)
$25.5M
EBIT (FY, 2022)
($42.1M)
Enterprise value
($23.6M)

Footer menu